Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: A retrospective analysis

Schizophrenia Research

Volumn 66, Issue 2-3, 2004, Pages 89-96

  Heresco Levy, Uriel ^a,b   Javitt, Daniel C ^c,d  

^a Ezrath Nashim Sarah Herzog Mem H   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Cognitive; Glutamate; Negative; NMDA; PANSS; Positive

Indexed keywords

CLOZAPINE; CYCLOSERINE; FLUPHENAZINE; GLYCINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SYMPTOM;

EID: 0348047434     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(03)00129-4     Document Type: Article

References (25)

1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. 1988;Lawrence Erlbaum Assoc. Hillsdale, NJ.
2. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1213-1215.
3. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-Cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry. 153:1996;1628-1630.
4. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., Hayden D.L., McCarley R., Coyle J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry. 56:1999;21-27.
5. Heresco-Levy U. Amino acid transmitter systems in schizophrenia and other psychotic disorders. D'haenen H., dem Boer J.A., Willner P. Biological Psychiatry. 2002;587-600 Wiley, London.
6. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry. 169:1996;610-617.
7. Heresco-Levy U., Javitt D.C., Ermilov M., Silipo G., Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int. J. Neuropsychopharmacol. 1:1998;131-136.
8. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 56:1999;29-36.
9. Heresco-Levy U., Ermilov M., Shimoni J., Shapira B., Silipo G., Javitt D.C. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry. 159:2002;480-482.
10. Hood W.F., Compton R.P., Monahan J.B. D-Cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci. Lett. 98:1989;91-95.
11. Hyman S.E., Arana B.W. Handbook of Psychiatric Drug Therapy. 1987;Little Brown, London.
12. Javitt D.C. Glycine modulators in schizophrenia. Curr. Opin. Investig. Drugs. 3:2002;1067-1072.
13. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
14. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1236.
15. Javitt D.C., Balla A., Sershen H., Lajtha A. A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry. 45:1999;668-679.
16. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4:2001;385-391.
17. Johnson J.W., Asher P. Glycine potentiates the NMDA responses in cultured mouse brain neurons. Nature. 325:1987;529-531.
18. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
19. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol. Psychiatry. 39:1996;213-215.
20. Nilsson M., Carlsson A., Carlsson M.L. Glycine and D-serine decrease MK-801-induced hyperactivity in mice. J. Neural Transm. 104:1997;1195-1205.
21. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry. 156:1998;145-147.
22. Rosse R.B., Fay-McCarthy M., Kendrick K., Davis R.E., Deutsch S.I. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin. Neuropharmacol. 19:1996;444-450.
23. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089.
24. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-Serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry. 156:1999;1822-1825.
25. Van Berckel B.N., Hijman R., van der Linden J.A., Westenberg H.G., van Ree J.M., Kahn R.S. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol. Psychiatry. 15:1996;1298-1300.